Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aim: Liver transplantation (LT) selection models for hepatocellular carcinoma (HCC) have not been proposed to predict waitlist dropout because of tumour progression. The aim of this study was to compare the alpha-foetoprotein (AFP) model and other pre-LT models in their prediction of HCC dropout.
Methods: A multicentre cohort study was conducted in 20 Latin American transplant centres, including 994 listed patients for LT with HCC from 2012 to 2018. Longitudinal tumour characteristics, and patterns of progression were recorded at time of listing, after treatments and at last follow-up over the waitlist period. Competing risk regression models were performed, and model's discrimination was compared estimating Harrell's adapted c-statistics.
Results: HCC dropout rate was significantly higher in patients beyond (24% [95% CI 16-28]) compared to those within Milan criteria (8% [95% IC 5%-12%]; p < .0001), with a SHR of 3.01 [95% CI 2.03-4.47]), adjusted for waiting list time and bridging therapies (c-index 0.63 [95% CI 0.57; 0.69). HCC dropout rates were higher in patients with AFP scores >2 (adjusted SHR of 3.17 [CI 2.13-4.71]), c-index of 0.71 (95% CI 0.65-0.77; p = .09 vs Milan). Similar discrimination power for HCC dropout was observed between the AFP score and the Metroticket 2.0 model. In patients within Milan, an AFP score >2 points discriminated two populations with a higher risk of HCC dropout (SHR 1.68 [95% CI 1.08-2.61]).
Conclusions: Pre-transplant selection models similarly predicted HCC dropout. However, the AFP model can discriminate a higher risk of dropout among patients within Milan criteria.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.15223 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Liver transplantation for intestinal malignancies.
Dig Liver Dis
August 2025
Department of Precision and Regenerative Medicine and Ionian Area, Hepatobiliary Surgery and Liver Transplant Unit, University of Bari Aldo Moro, Bari, Italy.
Liver transplantation (LT) is increasingly recognised as a valuable treatment option in carefully selected cases of metastatic intestinal cancers. While traditionally reserved for primary liver tumours such as hepatocellular carcinoma (HCC), recent evidence has broadened the transplant oncology paradigm to include colorectal liver metastases (CRLM) and neuroendocrine liver metastases (NELM). This review explores the evolving indications, patient selection criteria, and clinical outcomes of LT in these contexts, emphasising the need for a conceptual and methodological reassessment.
View Article and Find Full Text PDFImpact of Normothermic Machine Perfusion on Access to Liver Transplantation in Patients With Primary Hepatic Malignancies.
Clin Transplant
August 2025
Department of Surgery, Dumont-UCLA Transplant and Liver Cancer Centers, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Background: Balancing the probability of transplant and waitlist dropout in patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) using MELD exception points has been an enduring challenge. The advent of normothermic machine perfusion (NMP) has the potential to increase access to transplantation in patients with primary hepatic malignancies.
Methods: Using the Scientific Registry of Transplant Recipients database, this study evaluated the impact of widespread availability of NMP on access to liver transplantation in transplant oncology.
Re-emergence of early liver transplant access for hepatocellular carcinoma in the era of normothermic machine perfusion.
J Gastrointest Surg
September 2025
Division of Abdominal Transplantation, Stanford Transplant Outcomes Research Center, Stanford University Medical Center, Stanford, CA, United States. Electronic address:
Background: Since the Food and Drug Administration (FDA) approval of normothermic machine perfusion (NMP) in September 2021, liver transplantation (LT) numbers dramatically increased with shortened waitlist times. This is generally a positive trend. However, this might allow candidates with hepatocellular carcinoma (HCC) in the United States to receive LT without exception scores, for whom expedited transplant might not be ultimately beneficial.
View Article and Find Full Text PDFSex-based disparities in liver transplantation: Evidence from a nationwide Italian cohort.
JHEP Rep
June 2025
Gastroenterology, Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.
Background & Aims: Although sex-based disparities in the liver transplantation (LT) setting have been acknowledged for several years, particularly by studies conducted in the USA, data from European countries are scarce.
Methods: We conducted a nationwide, retrospective, observational study on candidates identified for LT in Italy between January 2017 and December 2021 using national registry data with follow-up until June 2023. The primary aim was to assess sex-based differences in LT access, analyzing delisting, retransplantation, and mortality rates.
The Italian Score for Organ Allocation: A Ten-Year Monocentric Retrospective Analysis in Liver Transplantation for Hepatocellular Carcinoma.
Cancers (Basel)
May 2025
Hepatobiliary and Transplant Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Background: The Italian Score for Organ Allocation (ISO), a transplant benefit oriented allocation system, was introduced in Italy in 2016. The main objective of this study is to identify risk factors for Drop-Out in hepatocellular (HCC) patients enlisted for LT before (Pre-ISO Era) and after ISO (ISO Era) introduction, while the secondary objective is to evaluate the survival results.
Methods: CIFs for liver transplantation and Drop-Out were estimated and compared between eras.